The Patent Finder
VT

Ventus Therapeutics U.S., Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

13 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2041
Next term end
5
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 4 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,319,319Compounds for Inhibiting NLRP3 and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,281,112Compounds for Inhibiting NLRP3 and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 12,312,350Compounds for Inhibiting NLRP3 and Uses Thereof
In force
 · Low confidence
In forceLow confidence
US 12,351,578Compounds for Inhibiting NLRP3 and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,618,751PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES
In force
 · High confidence
In forceHigh confidence
US 12,168,657PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 12,195,460PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 12,312,351PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
In force
 · Low confidence
In forceLow confidence
US 12,410,167Pyridazine Compounds for Inhibiting NLRP3
In force
 · Medium confidence
In forceMedium confidence
US 12,441,728Pyridazine Compounds for Inhibiting NLRP3
In force
 · Medium confidence
In forceMedium confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 21 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited